{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:04:08Z","timestamp":1792019048063,"version":"4.4.0"},"reference-count":84,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"philanthropic funding from the Epworth Medical and Snowdome Foundations"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bispecific antibodies (bsAbs) are an emerging therapy in the treatment of large B-cell lymphomas (LBCLs). There is a gap in the research on the safety and efficacy of bsAbs in adults with LBCL, with current research focusing on the wider non-Hodgkin\u2019s lymphoma population. To address this research gap, we conducted a systematic review aiming to evaluate the safety and efficacy outcomes of bsAbs in adults with LBCL. A systematized search was conducted in PubMed, EMBASE, and CENTRAL on 10 April 2024. Interventional clinical trials were eligible for inclusion. Observational studies, reviews, and meta-analyses were excluded. According to the Revised Risk of Bias Assessment Tool for Nonrandomized Studies, the included studies were largely of a high quality for safety outcome reporting, but of mixed quality for efficacy outcome reporting. Due to the heterogeneity of the included studies, the results were discussed as a narrative synthesis. Nineteen early phase studies were evaluated in the final analysis, with a pooled sample size of 1332 patients. Nine bsAbs were investigated across the studies as monotherapy (nine studies) or in combination regimes (10 studies). The rates of cytokine release syndrome were variable, with any grade events ranging from 0 to 72.2%. Infection rates were consistently high across the reporting studies (38\u201360%). Cytopenias were found to be common, in particular, anemia (4.4\u201362%), thrombocytopenia (3.3\u201369%), and neutropenia (4.4\u201370%). Immune effector cell-associated neurotoxicity syndrome (ICANS) and grade \u22653 adverse events were not commonly reported. Promising efficacy outcomes were reported, with median overall response rates of 95\u2013100% in the front-line and 36\u201391% in terms of relapsed\/refractory disease. The results of this systematic review demonstrate that bsAbs are generally well-tolerated and effective in adults with LBCL. BsAbs appear to have superior tolerability, but inferior efficacy to CAR T-cell therapies in adults with LBCL. Future research on safety and efficacy should focus on evaluating adverse event timing and management, the impact on the patient\u2019s quality of life, the burden on the healthcare system, and overall survival outcomes.<\/jats:p>","DOI":"10.3390\/ijms25179736","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T05:59:08Z","timestamp":1725861548000},"page":"9736","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data"],"prefix":"10.3390","volume":"25","author":[{"given":"Elena","family":"Bayly-McCredie","sequence":"first","affiliation":[{"name":"Epworth HealthCare, East Melbourne, VIC 3002, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Treisman","sequence":"additional","affiliation":[{"name":"Epworth HealthCare, East Melbourne, VIC 3002, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-2215","authenticated-orcid":false,"given":"Salvatore","family":"Fiorenza","sequence":"additional","affiliation":[{"name":"Epworth HealthCare, East Melbourne, VIC 3002, Australia"},{"name":"Faculty of Medicine and Health, University of Sydney, Camperdown, NSW 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kurz, K.S., Ott, M., Kalmbach, S., Steinlein, S., Kalla, C., Horn, H., Ott, G., and Staiger, A.M. (2023). Large B-cell lymphomas in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new concepts. Cancers, 15.","DOI":"10.3390\/cancers15082285"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_3","unstructured":"Australian Institue of Health and Welfare (2024, May 10). Cancer data in Australia: Australian Institue of Health and Welfare, Available online: https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/blood-cancer-incidence-and-survival-by-histology-e."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/EDBK_349307","article-title":"Revising the treatment pathways in lymphoma: New standards of care\u2014How do we choose?","volume":"42","author":"Ngu","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2321648","DOI":"10.1080\/2162402X.2024.2321648","article-title":"Trial watch: Bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma","volume":"13","author":"Cassanello","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Balendran, S., Tam, C., and Ku, M. (2023). T-cell engaging antibodies in diffuse large B cell lymphoma-an update. J. Clin. Med., 12.","DOI":"10.3390\/jcm12216737"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/19420862.2018.1558698","article-title":"Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor\/CD19 association leading to impaired B-cell proliferation","volume":"11","author":"Hatterer","year":"2019","journal-title":"MAbs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Zweegman","year":"2023","journal-title":"Lancet"},{"key":"ref_12","unstructured":"U.S. Food and Drug Administration (2024, May 10). FDA Grants Accelerated Approval to Epcoritamab-Bysp for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell."},{"key":"ref_13","unstructured":"U.S. Food and Drug Administration (2024, May 10). FDA Grants Accelerated Approval to Glofitamab-Gxbm for Selected Relapsed or Refractory Large B-Cell Lymphomas: FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/lymphatics1030015","article-title":"Understanding the role of bispecific antibodies in the management of B-cell non-Hodgkin lymphoma: A new immunotherapy that is here to stay","volume":"1","author":"Ivanov","year":"2023","journal-title":"Lymphatics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: Current data and perspectives","volume":"14","author":"Dulery","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Salvaris, R., Ong, J., and Gregory, G.P. (2021). Bispecific antibodies: A review of development, clinical efficacy and toxicity in B-cell lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/onco.13915","article-title":"Clinical outcomes, treatment toxicity, and health care utilization in older adults with aggressive non-Hodgkin lymphoma","volume":"26","author":"Johnson","year":"2021","journal-title":"Oncologist"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2021-149735","article-title":"Impact of comorbidities on outcomes and toxicity in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): A multicenter RWE study","volume":"138","author":"Shouse","year":"2021","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Dendle, C., Gilbertson, M., Spelman, T., Stuart, R.L., Korman, T.M., Thursky, K., Opat, S., and McQuilten, Z. (2017). Infection is an independent predictor of death in diffuse large B cell lymphoma. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-04495-x"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1182\/blood-2023-185138","article-title":"Infections in lymphoma patients treated with bispecific therapies: A systematic review and meta-analysis","volume":"142","author":"Reynolds","year":"2023","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: A systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"key":"ref_24","unstructured":"The EndNote Team (2023). EndNote, Clarivate. EndNote 21.3."},{"key":"ref_25","unstructured":"(2024). Covidence, Veritas Health Innovation."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"i5078","DOI":"10.1136\/bmj.i5078","article-title":"Recommendations to improve adverse event reporting in clinical trial publications: A joint pharmaceutical industry\/journal editor perspective","volume":"355","author":"Lineberry","year":"2016","journal-title":"Br. Med. J."},{"key":"ref_27","unstructured":"NLM (2024, May 26). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4082\/kjfm.23.0034","article-title":"RoBANS 2: A revised risk of bias assessment tool for nonrandomized studies of interventions","volume":"44","author":"Seo","year":"2023","journal-title":"Korean J. Fam. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2023-174668","article-title":"Double step-up dosing (2SUD) regimen mitigates severe ICANS and CRS while maintaining high efficacy in subjects with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) treated with AZD0486, a novel CD19xCD3 T-cell engager (TCE): Updated safety and efficacy data from the ongoing first-in-human (FIH) phase 1 trial","volume":"142","author":"Gaballa","year":"2023","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/blood-2022-169171","article-title":"First-in-human (FIH) study of the fully-human kappa-lambda CD19\/CD47 bispecific antibody TG-1801 in patients (pts) with B-cell lymphoma","volume":"140","author":"Hawkes","year":"2022","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2023-188854","article-title":"Feasibility and safety of the first-in-human chemotherapy-light combination of rituximab, polatuzumab vedotin and glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 uears of age ineligible for a fully dosed R-CHOP-R-Pola-Glo\/Ikf-t062, a study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)","volume":"142","author":"Melchardt","year":"2023","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2019-123978","article-title":"CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody atezolizumab in relapsed or refractory B-cell non-hodgkin lymphoma","volume":"134","author":"Hutchings","year":"2019","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hon.3163_91","article-title":"Combining CD19-4-1BBL (RO7227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"41","author":"Hutchings","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S431","DOI":"10.1016\/S2152-2650(23)01319-8","article-title":"Epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit\/ triple-hit lymphoma: Updated EPCORE NHL-2 data","volume":"23","author":"Falchi","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2023-180935","article-title":"Epcoritamab SC + R-Mini-CHOP leads to high complete metabolic response rates in patients with previously untreated diffuse large B-cell lymphoma ineligible for full-dose R-CHOP: First disclosure from arm 8 of the EPCORE NHL-2 trial","volume":"142","author":"Vermaat","year":"2023","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2023-180246","article-title":"Epcoritamab SC + GemOx leads to high complete metabolic response rates in patients with relapsed\/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant: Updated results from Epcore NHL-2","volume":"142","author":"Brody","year":"2023","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1200\/JCO.2022.40.16_suppl.7528","article-title":"Subcutaneous epcoritamab + R-DHAX\/C in patients (pts) with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1\/2 results","volume":"40","author":"Abrisqueta","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2023-180333","article-title":"Mitigating the risk of cytokine release syndrome (CRS): Preliminary results from a DLBCL cohort of Epcore NHL-1","volume":"142","author":"Vose","year":"2023","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma: Recommended dose safety\/efficacy update and escalation exposure-response analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2023-188444","article-title":"GB261, an Fc-function enabled and CD3 affinity de-tuned CD20\/CD3 bispecific antibody, demonstrated a highly advantageous safety\/efficacy balance in an ongoing first-in-human dose-escalation study in patients with relapsed\/refractory non-Hodgkin lymphoma","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: Safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: Clinical management experience from a pivotal phase I\/II trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: A phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_50","unstructured":"NCI (2024, May 23). Common Terminology Criteria for Adverse Events (CTCAE), Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Hawkes, E., Lewis, K.L., Wong Doo, N., Patil, S.S., Miskin, H.P., Sportelli, P., Kolibaba, K.S., Normant, E., Turpuseema, T., and Cheah, C.Y. (2022, January 11). First-in-human (FIH) study of the fully-human kappa-lambda CD19\/CD47 bispecific antibody TG-1801 in patients (pts) with B cell lymphoma. Proceedings of the American Society of Hematology 64th Congress, New Orleans, LA, USA.","DOI":"10.1182\/blood-2022-169171"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing side effects: Guidance for use of immunotherapies in multiple myeloma","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2040620719899897","DOI":"10.1177\/2040620719899897","article-title":"Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia","volume":"11","author":"Jain","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"769","DOI":"10.31557\/APJCP.2023.24.3.769","article-title":"Prevalence and impact of fatigue on quality of life (QOL) of cancer patients undergoing chemotherapy: A systematic review and meta-analysis","volume":"24","author":"Muthanna","year":"2023","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/psp4.12192","article-title":"Time-to-event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens","volume":"6","author":"Lu","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Cosenza, M., Sacchi, S., and Pozzi, S. (2021). Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147652"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: Dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"key":"ref_71","first-page":"e104","article-title":"Glofitamab plus gemcitabine and oxaliplatin (Glofit-Gemox) for relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): Results of a global randomized phase III trial (STARGLO)","volume":"8","author":"Abramson","year":"2024","journal-title":"HemaSphere"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Reeves, B.C., Deeks, J.J., Higgins, J.P., Shea, B., Tugwell, P., Wells, G.A., and Cochrane Non-Randomized Studies of Interventions Methods Group (2019). Including non-randomized studies on intervention effects. Cochrane Handbook for Systematic Reviews of Interventions, Wiley Online Library.","DOI":"10.1002\/9781119536604.ch24"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"Br. Med. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: Meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"Br. Med. J."},{"key":"ref_77","unstructured":"NLM (2024, June 15). A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Compared to Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma (SUNMO), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05171647?intr=Mosunetuzumab&page=3&rank=24."},{"key":"ref_78","unstructured":"NLM (2024, June 15). A Phase 3 Trial of Epcoritamab vs Investigator\u2019s Choice Chemotherapy in R\/R DLBCL (EPCORE DLBCL-1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04628494?intr=Epcoritamab&page=2&rank=16#study-plan."},{"key":"ref_79","unstructured":"NLM (2024, June 15). An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06047080?intr=Glofitamab&page=3&rank=21."},{"key":"ref_80","unstructured":"NLM (2024, June 15). A Trial to Learn How Effective and Safe Odronextamab Is Compared to Standard of Care for Adult Participants with Previously Treated Aggressive B-Cell Non-Hodgkin Lymphoma (OLYMPIA-4), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06230224?intr=Odronextamab&rank=10."},{"key":"ref_81","unstructured":"NLM (2024, June 15). A Study to Compare How Well Odronextamab Combined with Chemotherapy Works and How Safe It Is against Rituximab Combined with Chemotherapy, in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (OLYMPIA-3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06091865?intr=Odronextamab&rank=7."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood-2019-128564","article-title":"Preliminary safety and anti-tumor activity of XmAb13676, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: Extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res. Synth. Methods"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9736\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:52:03Z","timestamp":1760111523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":84,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179736"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179736","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]}}}